Published in Cancer Weekly, April 22nd, 2003
Virulizin showed significant antitumor activity as a monotherapy and enhanced antitumor effects when used in combination with standard chemotherapy agents against a panel of human pancreatic tumors and melanoma.
Data describing the pharmacological activity of Virulizin as reported in Cancer Chemotherapy and Pharmacology, will be an important addition to the preclinical component of regulatory dossiers required to obtain marketing approval for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.